The Hetero Ring Contains Chalcogen Patents (Class 540/467)
  • Patent number: 9993460
    Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: June 12, 2018
    Assignee: RACE ONCOLOGY LTD.
    Inventors: William J. Garner, Amie Franklin, John Rothman
  • Patent number: 9974774
    Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: May 22, 2018
    Assignee: RACE ONCOLOGY LTD.
    Inventors: William J. Garner, Amie Franklin, John Rothman
  • Patent number: 9790499
    Abstract: Functionally-modified oligonucleotide analogs comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: October 17, 2017
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventors: Gunnar J. Hanson, Dwight D. Weller, Bao Zhong Cai, Ming Zhou
  • Patent number: 9278987
    Abstract: Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: March 8, 2016
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Gunnar J. Hanson, Dwight D. Weller, Bao Zhong Cai, Ming Zhou
  • Patent number: 9034861
    Abstract: The invention pertains to compound of Formula (I) wherein X, Y, Z, R1, R2, R3, R4, A and A? are as described hereinabove. Formula (I) and (II) compounds can be used in pharmaceutical compositions, useful for the treatment of diseases.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: May 19, 2015
    Assignee: Allomek Therapeutics LLC
    Inventors: Uday R. Khire, Mahendra Devichand Chordia
  • Patent number: 9035042
    Abstract: The invention concerns the production of quinoline compounds containing sulfonic acid groups, the said quinoline compounds and their conversion into dyes containing sulfonic acid groups. The dyes according to the invention are used especially to label analytes, for example to label biomolecules.
    Type: Grant
    Filed: July 2, 2004
    Date of Patent: May 19, 2015
    Assignee: ATTO-TEC GmbH
    Inventors: Alexander Zilles, Jutta Arden-Jacob, Karl-Heinz Drexhage, Norbert Uwe Kemnitzer, Monika Hamers-Schneider
  • Patent number: 8906852
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: December 9, 2014
    Assignee: MethylGene Inc.
    Inventors: Stéphane Raeppel, Franck Raeppel, Stephen William Claridge, Lijie Zhan, Frédéric Gaudette, Michael Mannion, Norifumi Sato, Yohei Yuki, Masashi Kishida, Arkadii Vaisburg
  • Patent number: 8900780
    Abstract: Disclosed are a photosensitive resin composition for a color filter and a color filter using the same. The photosensitive resin composition for a color filter includes (A) a dye represented by the following Chemical Formula 1, (B) an alkali soluble resin, (C) a photopolymerizable monomer, (D) a photopolymerization initiator, and (E) a solvent.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: December 2, 2014
    Assignee: Cheil Industries Inc.
    Inventors: Jae-Hyun Kim, Kyung-Soo Moon, Myoung-Youp Shin, Dong-Hoon Won, Seung-Hyun Kim, Atsushi Endo, Hwan-Sung Cheon, Gyu-Seok Han
  • Publication number: 20140342997
    Abstract: Present invention refers to complex-forming compounds of the general formula and the use and preparation thereof.
    Type: Application
    Filed: December 28, 2012
    Publication date: November 20, 2014
    Applicant: STRATOXER(S) KFT.
    Inventors: G. Imre Csizmadia, Zoltan Mucsi, Andrea Narcisz Koczkas
  • Publication number: 20140330006
    Abstract: Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Application
    Filed: November 15, 2012
    Publication date: November 6, 2014
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Gunnar J. Hanson, Dwight D. Weller, Bao Zhong Cai, Ming Zhou
  • Patent number: 8852846
    Abstract: The present invention provides a salt represented by the formula (I): wherein Q1 and Q2 independently each represent a fluorine atom or a C1-C6 perfluoroalkyl group, L1 represents a C1-C20 divalent saturated hydrocarbon group in which one or more —CH2— can be replaced by —O— or —CO—, W represents a group represented by the formula (W1), (W2), (W3), (W4) or (W5): and Z+ represents an organic counter ion.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: October 7, 2014
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Yukako Anryu, Koji Ichikawa
  • Patent number: 8841285
    Abstract: Provided herein include compositions, all related stereoisomers as well as pharmaceutically acceptable salts provided as simplified analogs of pateamine A, in which the analogs generally are devoid of the C3-amino and C5-methyl groups, also referred to as desmethyl, desamino-pateamine A. Suitable analogs provide anticancer and antiproliferative effects in vivo and in vitro by a novel drugs mechanism of action described herein for pateamine A, including inhibition of eIF4A-dependent translation initiation. As with pateamine A, as described herein, suitable analogs cause cell cycle arrest or induce apoptosis in transformed cells. However, toxicity of such compounds to slow growing normal cells is low. In addition, such analogs, like pateamine A, target translation initiation factors and are useful as anticancer and antiproliferative agents in subjects in need thereof.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: September 23, 2014
    Assignees: The Texas A&M University System, The John Hopkins University
    Inventors: Daniel Romo, Jun Liu, Nam Song Choi, Zonggao Shi, Woon-Kai Low, Yongjun Dang, Tilman Schneider-Poetsch
  • Publication number: 20140187527
    Abstract: The present disclosure provides a novel class of macrocyclic compounds and their metal complexes formed with transition metal ion, lanthanide metal ions and other metal ions (e.g., Al, Ga, Y, In, Sn, Tl, Pb and Bi) and their applications in the fields of contrast agents, artificial nucleases, fluorescence probes, nuclear medicines and other biomedical applications in the therapeutics or diagnostics.
    Type: Application
    Filed: December 31, 2012
    Publication date: July 3, 2014
    Applicant: NATIONAL YANG MING UNIVERSITY
    Inventors: Cheng Allen Chang, Ren-Shyan Liu, Bhalchandra Vishnu Bhagwat
  • Patent number: 8722882
    Abstract: The present invention relates to Pyriraidine Derivatives of formula (I), compositions comprising a Pyrimidine Derivative, and methods of using the Pyrimidine Derivatives for treating or preventing obesity, diabetes, a diabetic complication, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G protein-coupled receptor (GPCR) in a patient.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: May 13, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Bernard R. Neustadt, Andrew Stamford, Jinsong Hao, Charles Lee Jayne, Yan Xia
  • Patent number: 8697704
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: April 15, 2014
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yao-Ling Qiu, Xiaowen Peng, Ce Wang, Yat Sun Or
  • Publication number: 20140081017
    Abstract: The present invention relates to compositions and methods to selectively treat fungal infection. More particularly, the invention relates to compounds, compositions thereof, and methods for selectively enhancing fungal sensitivity to antifungal compounds.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 20, 2014
    Applicant: METHYLGENE INC.
    Inventor: METHYLGENE INC.
  • Publication number: 20130344607
    Abstract: The present invention relates to ?-conjugated fluoroionophores, methods for their preparation, and their use and a method for determining an alkali ion. Fluoroionophoric compounds of the general formula I are described Ionophore-?-Linker-Fluorophore??(I) wherein the Ionophore is an anilino containing crown ether or cryptand with one or more anilino donor moieties as electron donors, forming a stable complex with an alkali metal ion the ?-Linker is an aromatic or heteroaromatic conjugative linking moiety, and the Fluorophore is an electron acceptor moiety. Variation of the ionophoric unit offers a broad spectrum of detectable K+ and Na+-concentrations, ranging from high concentration around 800 mM down to very low concentrations around 3 mM.
    Type: Application
    Filed: March 9, 2012
    Publication date: December 26, 2013
    Applicant: UNIVERSITAET POTSDAM
    Inventors: Sandra Ast, Hans-Juergen Holdt
  • Patent number: 8614317
    Abstract: The invention concerns the production of quinoline compounds containing sulfonic acid groups, the said quinoline compounds and their conversion into dyes containing sulfonic acid groups. The dyes according to the invention are used especially to label analytes, for example to label biomolecules.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: December 24, 2013
    Assignee: Atto-Tec GmbH
    Inventors: Alexander Zilles, Jutta Arden-Jacob, Karl-Heinz Drexhage, Norbert Uwe Kemnitzer, Monika Hamers-Schneider
  • Patent number: 8557980
    Abstract: Described are methods of forming protected boronic acids that provide in a manner that is straightforward, scalable, and cost-effective a wide variety of building blocks, such as building blocks containing complex and/or pharmaceutically important structures, and/or provide simple or complex protected organoboronic acid building blocks. A first method includes reacting an imino-di-carboxylic acid and an organoboronate salt. A second method includes reacting a N-substituted morpholine dione and an organoboronic acid.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: October 15, 2013
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Martin D. Burke, Graham R. Dick, David M. Knapp, Eric P. Gillis, Jenna A. Klubnick
  • Patent number: 8540966
    Abstract: The present invention relates to a novel class of paramagnetic ion-based contrast agents of formula (I), wherein a chelating backbone moiety is highly functionalized by the presence of one or more polyhydroxylated chain, that show a pharmacokinetic profile analogous to that of the commonly used T1-general extravascular agents (NSA) but are further characterized by a higher relaxivity.
    Type: Grant
    Filed: June 28, 2005
    Date of Patent: September 24, 2013
    Assignee: Bracco Imaging S.p.A.
    Inventors: Silvio Aime, Matteo Galli, Luciano Lattuada, Pierfrancesco Morosini, Fulvio Uggeri, Kondareddiar Ramalingam
  • Patent number: 8518715
    Abstract: A bifunctional polyazamacrocyclic chelating agent of the formula (I): wherein: and the variables A, L, Q, Q1, X, Y, Z, Z1, m, n and r are as defined in the description of the present application. Also described is a complex of the above chelating agent to an ion of a metal ion, such as an ion of 90Y, 111In or 177Lu; a conjugate of the complex covalently attached to a biological carrier; and a pharmaceutical composition containing the conjugate. A method of therapeutic treatment of a mammal involving administration of the pharmaceutical composition is also described.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: August 27, 2013
    Assignee: Nordion (Canada) Inc.
    Inventors: Zoltan Kovacs, Garry E. Kiefer, Corinne Bensimon, A. Dean Sherry, Gyula Tircso, Cara Ferreira
  • Publication number: 20130190488
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.
    Type: Application
    Filed: December 12, 2012
    Publication date: July 25, 2013
    Applicant: Abbott Laboratories
    Inventor: Abbott Laboratories
  • Publication number: 20130096088
    Abstract: The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling.
    Type: Application
    Filed: September 27, 2012
    Publication date: April 18, 2013
    Applicant: METHYLGENE INC.
    Inventor: METHYLGENE INC.
  • Publication number: 20130045939
    Abstract: The invention relates to fatty and macrolide derivatives; compositions comprising an effective amount of fatty acid macrolide derivative; and methods for treating or preventing an autoimmune disorders and diseases with inflammation as the underlying etiology comprising the administration of an effective amount of a fatty acid macrolide derivative.
    Type: Application
    Filed: March 18, 2011
    Publication date: February 21, 2013
    Applicant: CATABASIS PHARMACEUTICALS, INC.
    Inventors: Chi B. Vu, Jean E. Bemis, Michael R. Jirousek, Jill C. Milne
  • Publication number: 20120323000
    Abstract: The present invention relates generally to olefin metathesis. In some embodiments, the present invention provides methods for Z-selective ring-closing metathesis.
    Type: Application
    Filed: June 1, 2012
    Publication date: December 20, 2012
    Applicants: TRUSTEES OF BOSTON COLLEGE, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Amir H. Hoveyda, Miao Yu, Chenbo Wang, Richard R. Schrock
  • Publication number: 20120258995
    Abstract: The present invention relates to new indolinone compounds and their pharmaceutically acceptable salts and prodrugs for treating and preventing VEGFR related cellular disorders such as cancer.
    Type: Application
    Filed: April 6, 2012
    Publication date: October 11, 2012
    Applicant: Beta Pharma, Inc
    Inventors: Don Zhang, Guojian Xie
  • Publication number: 20120251560
    Abstract: The present invention provides inventive conjugated polyethyleneimine (PEI) polymers and conjugated aza-macrocycles (collectively referred to herein as “conjugated lipomers” or “lipomers”) containing one or more groups of the formula (iii): wherein R3 and R4 are as defined herein. Also provided are compositions comprising the inventive conjugated lipomers, and methods of preparation and use.
    Type: Application
    Filed: March 23, 2012
    Publication date: October 4, 2012
    Applicant: Massachusetts Institute of Technology
    Inventors: James E. Dahlman, Avraham D. Schroeder, Daniel Griffith Anderson, Robert S. Langer, Christopher G. Levins
  • Publication number: 20120238747
    Abstract: Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having the general structure: wherein Q is selected from the group consisting of N, O and S; L is any bivalent organic radical capable of linking each Q, such as C, CH, (CH2)l, or {(CH2)i-Y—(CH2)j}k, wherein Y is selected from the group consisting of CH2, an ether, a polyether, an amide, a polyamide, an ester, a sulfide, a urea, a thiourea, a guanidyl, a carbamoyl, a carbonate, a phosphate, a sulfate, a sulfoxide, an imine, a carbonyl, and a secondary amino group and wherein Y is optionally substituted by —X1-L?-X2—Z or —Z; R1-R6, independently of one another, are selected from the group consisting of H, —(CH2)p-D-Z, an alkyl, an alkenyl, an aryl, and an alkyl or alkyl ether optionally substituted by one or more of an alcohol, an aminoalcohol, an amine, an amide, an ether, a polyether, a polyamide, an ester, a mercaptan, an alkylthio, a urea, a thiourea, a guanidyl, or a carbamoyl group, and
    Type: Application
    Filed: March 14, 2012
    Publication date: September 20, 2012
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Yongliang CHU, Malek Masoud, Gulilat Gebeyehu
  • Publication number: 20120226033
    Abstract: The present invention relates to novel benzene-carboxamide compounds having a structure that corresponds to the general formula (I) below: and also to their method of synthesis and to their use in pharmaceutical compositions intended for use in human or veterinary medicine or else to their use in cosmetic compositions.
    Type: Application
    Filed: September 16, 2010
    Publication date: September 6, 2012
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Laurence Clary, Jean-Claude Pascal
  • Patent number: 8232390
    Abstract: The present invention relates to pentacyclic indole derivatives of formula (I): wherein A, Ar, R1, R2, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.
    Type: Grant
    Filed: May 4, 2007
    Date of Patent: July 31, 2012
    Assignee: Istituto di Richerche di Biologia Molecolare P. Angeletti SpA
    Inventors: Elena Capito, Joerg Habermann, Frank Narjes, Maria del Rosario Rico Ferreira, Ian Stansfield
  • Patent number: 8198101
    Abstract: A bifunctional polyazamacrocyclic chelating agent of the formula (I): wherein: and the variables A, L, Q, Q1, X, Y, Z, Z1, m, n and r are as defined in the description of the present application. Also described is a complex of the above chelating agent to an ion of a metal ion, such as an ion of 90Y, 111Li or 177Lu; a conjugate of the complex covalently attached to a biological carrier; and a pharmaceutical composition containing the conjugate. A method of therapeutic treatment of a mammal involving administration of the pharmaceutical composition is also described.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: June 12, 2012
    Assignee: Nordion (Canada) Inc.
    Inventors: Zoltan Kovacs, Garry E. Kiefer, Corinne Bensimon, A. Dean Sherry, Gyula Tircso
  • Publication number: 20120065169
    Abstract: Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Application
    Filed: May 27, 2011
    Publication date: March 15, 2012
    Inventors: Gunnar J. Hanson, Alexander Charles Rudolph, Bao Zhong Cai, Ming Zhou, Dwight D. Weller
  • Publication number: 20120035159
    Abstract: The present invention provides an isoquinoline-6-sulfonamide derivative that is useful as a novel pharmaceutical agent. The present invention provides an isoquinoline-6-sulfonamide derivative represented by Formula (1), a salt thereof, or a solvate of the derivative or the salt: wherein X and Y each independently represent a direct bond, NH, CH?CH, O, or S; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, an alkyl group, or the like; R3 and R4 each independently represent a hydrogen atom, an alkyl group, or the like, or R3 and R4 together form an alkylene group or an alkenylene group, which may be bridged between two carbon atoms to an arbitrary position; and l, m, and n represent an integer number of 1 to 4.
    Type: Application
    Filed: June 18, 2010
    Publication date: February 9, 2012
    Applicant: D. WESTERN THERAPEUTICS INSTITUTE, INC
    Inventors: Hiroyoshi Hidaka, Kouichi Takahashi, Yoshihiro Inoue, Kengo Sumi, Ryohei Nakamura
  • Publication number: 20120035255
    Abstract: The present invention relates to compounds having general formula (I), i.e. poly-alkyl-bis-maltolic molecules and in particular to derivates of [(3-hydroxy-4-pyron-2-yl)methyl]-amine and pharmaceutically acceptable salts thereof, and to the use thereof as anti-neoplastic drugs, in particular, for the preparation of a medicament for the treatment of neoplastic diseases.
    Type: Application
    Filed: November 27, 2009
    Publication date: February 9, 2012
    Applicant: Universita' Degli Studi Di Urbino
    Inventors: Mirco Fanelli, Vieri Fusi
  • Patent number: 8110679
    Abstract: Nanofilms useful for filtration are prepared from oriented amphiphilic molecules and oriented macrocyclic modules. The amphiphilic species may be oriented on an interface or surface. The nanofilm may be prepared by depositing or attaching an oriented layer to a substrate. A nanofilm may also be prepared by coupling the oriented macrocyclic modules to provide a membrane.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: February 7, 2012
    Assignee: Covalent Partners LLC
    Inventors: Joshua W. Kriesel, Timothy B. Karpishin, Donald B. Bivin, Grant Merrill, Martin S. Edelstein, Thomas H. Smith, Jeffery A. Whiteford, Robert T. Jonas, Mark Micklatcher, Serena Joshi
  • Publication number: 20120009519
    Abstract: The present invention provides a compound represented by the formula (I): wherein R1 represents a hydrogen atom, a halogen atom or a C1-C6 alkyl group which may have one or more halogen atoms, A1 represents a divalent connecting group, X1 represents a C2-C36 heterocyclic group and one or more —CH2— in the C2-C36 heterocyclic group can be replaced by —CO— or —O—, R2 is independently in each occurrence a halogen atom, a hydroxyl group, a C1-C24 hydrocarbon group, a C1-C12 alkoxy group, a C2-C4 acyl group or a C2-C4 acyloxy group, and m represents an integer of 0 to 10.
    Type: Application
    Filed: July 1, 2011
    Publication date: January 12, 2012
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Hyungjoo KIM, Akira KAMABUCHI, Yuichi MUKAI
  • Publication number: 20110257100
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.
    Type: Application
    Filed: April 8, 2011
    Publication date: October 20, 2011
    Inventors: Stëphane Raeppel, Franck Raeppel, Stephen William Claridge, Lijie Zhan, Frëdëric Gaudette, Michael Mannion, Norifumi Sato, Yohei Yuki, Masashi Kishida, Arkadii Vaisburg
  • Publication number: 20110257254
    Abstract: The invention relates to adamantane diaza-crown ether derivatives and the use of mono and diaza-crown ether adamantine derivatives in treatment, especially in tumor treatment. Adamantane aza-crown ethers were obtained by reaction of the corresponding adamantane derived tosylates or adamantane acid chlorides with mono- and diaza-18-crown-6. The prepared compounds showed moderate (monoaza-18-crown-6) to strong (diaza-18-crown-6) antiproliferative and cytotoxic activity on several tumor cell lines, revealing their potential for inhibiting the growth of other tumor cells.
    Type: Application
    Filed: May 13, 2011
    Publication date: October 20, 2011
    Inventors: Marijeta Kralj, Kata Majerski, Tatjana Sumanovac Ramljak, Marko Marjanovic
  • Publication number: 20110224427
    Abstract: This invention relates to sulfur based compounds useful in methods of carbon dioxide or sulfur dioxide removal.
    Type: Application
    Filed: March 11, 2011
    Publication date: September 15, 2011
    Applicant: E. I. DU PONT DE NEMOURS AND COMPANY
    Inventor: Mark A. Scialdone
  • Patent number: 8003784
    Abstract: Methods for preparing cyclic carbamates and thiocarbamates containing cyanopyrrole moieties and of the formula are provided. Z are the same or different and are H, optionally substituted C1 to C6 alkyl, or CORA; RA is H, optionally substituted C1 to C6 alkyl, optionally substituted C1 to C6 alkoxy, or optionally substituted C1 to C6 aminoalkyl; Q are the same or different and are H, OH, NH2, CN, halogen, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C1 to C6 alkynyl, optionally substituted C1 to C6 alkoxy, optionally substituted C1 to C6 aminoalkyl, or CORB; and RB is H, optionally substituted C1 to C6 alkyl, optionally substituted C1 to C6 alkoxy, or optionally substituted C1 to C6 aminoalkyl.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: August 23, 2011
    Assignee: Wyeth LLC
    Inventor: Bogdan Kazimierz Wilk
  • Publication number: 20110190293
    Abstract: Quinazolinone compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
    Type: Application
    Filed: April 12, 2011
    Publication date: August 4, 2011
    Inventors: Weibo Wang, Liana M. Lagniton, Ryan N. Constantine, Manoj C. Desai
  • Publication number: 20110190486
    Abstract: The invention concerns the production of quinoline compounds containing sulfonic acid groups, the said quinoline compounds and their conversion into dyes containing sulfonic acid groups. The dyes according to the invention are used especially to label analytes, for example to label biomolecules.
    Type: Application
    Filed: March 25, 2011
    Publication date: August 4, 2011
    Applicant: ATTO-TEC GMBH
    Inventors: Alexander Zilles, Jutta Arden-Jacob, Karl-Heinz Drexhage, Norbert Uwe Kemnitzer, Monika Hamers-Schneider
  • Publication number: 20110178130
    Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Application
    Filed: May 22, 2009
    Publication date: July 21, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Christopher Kallus, Mark Broenstrup, Andreas Evers, Anja Globisch, Herman Schreuder, Michael Wagner
  • Patent number: 7973030
    Abstract: A pharmaceutical useful as a therapeutic agent and a preventive agent for hyperlipemia, and a pharmaceutical useful as a therapeutic agent and a preventive agent for hepatic disorders associated with cholestasis, particularly, primary biliary cirrhosis and primary sclerosing cholangitis, and a pharmaceutical useful as a therapeutic agent and a preventive agent for obesity, fatty liver and steatohepatitis are provided.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: July 5, 2011
    Assignee: Asahi Kasei Pharma Corporation
    Inventors: Takehiko Sasahara, Mitsunobu Mohri, Ken-Ichi Kasahara
  • Patent number: 7964721
    Abstract: A mercury selective fluorescent chemosensor for detecting mercury ions by a compound represented by formula 1 and a novel fluorescent sensitive compound prepared by introducing two aminopyrene functions as a fluorescent sensitive moiety into a binding site of the compound of formula 1 is used for selectively detecting mercury ions are provided. The mercury selective fluorescent sensitive chemosensor is a switch type chemosensor having ON-OFF-type Hg2+-selective fluorescence quenching behavior and is not affected by other coexistent metal ions. Changes in fluorescence of the compounds of formula 1 were analyzed by ratiometric approach using monomer and excimer emissions of the pyrene fluorophore to selectively signal the concentration of mercury ions. The chemosensor can detect mercury ions in a micromolar unit even in a solution including an excess of water. Accordingly, the mercury selective fluorescent chemosensor for detecting mercury ions can be used effectively in environmental and medical applications.
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: June 21, 2011
    Assignee: Chung-Ang University Industry-Academy Cooperation Foundation
    Inventors: Suk-Kyu Chang, Jun Soo Kim, Myung Gil Choi, Ki Cheol Song, Sangdoo Ahn, Kyoung Tai No
  • Publication number: 20110118330
    Abstract: Compounds that inhibit proteolytic enzymes of Human Immunodeficiency Virus (HIV) are described. Preparation of the inhibitors, pharmaceutical compositions containing them, and uses of the compounds or compositions for the treatment of HIV infections are also described.
    Type: Application
    Filed: July 8, 2009
    Publication date: May 19, 2011
    Applicant: PURDUE RESEARCH FOUNDATION
    Inventor: Arun K. Ghosh
  • Publication number: 20110059959
    Abstract: The present invention is directed to novel multicyclic molecules that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of PARP, VEGFR2, and MLK3 enzymes, including, for example, neurodegenerative diseases, inflammation, ischemia, and cancer.
    Type: Application
    Filed: November 18, 2010
    Publication date: March 10, 2011
    Applicant: CEPHALON, INC.
    Inventors: Sankar Chatterjee, James L. Diebold, Derek Dunn, Robert L. Hudkins, Reddeppareddy Dandu, Gregory J. Wells, Allison L. Zulli
  • Publication number: 20110039815
    Abstract: In one embodiment the present invention relates to a method of treating cancerous cells in a mammal comprising the steps of administering to the cancerous cells an effective amount of a cyclic amine wherein the cyclic amine contains sulfur or nitrogen and the structure includes an interchealted metal ion.
    Type: Application
    Filed: June 14, 2006
    Publication date: February 17, 2011
    Inventors: Wiley J. Youngs, Claire A. Tessier, Doug A. Medvetz, Michael J. Taschner
  • Patent number: 7858383
    Abstract: The invention relates to methods of determining sodium ions in a sample, wherein the ions are contacted with a compound having chromophoric moiety and an ionophoric moiety, where the ionophoric moiety interacts with the sodium ions present in the sample, resulting in the chromophoric moiety changing its radiation absorption properties in the ultraviolet and visible regions of the spectrum. For example, a change in an intensity of an absorption maximum is measured and the ion concentration is determined accordingly.
    Type: Grant
    Filed: May 2, 2007
    Date of Patent: December 28, 2010
    Assignee: Opti Medical Systems
    Inventors: Huarui He, Chao Lin, Neeta Raje, Chusheng Liu
  • Patent number: 7851496
    Abstract: Disclosed relates to an ionic liquid type crown ether derivative, expressed by Chemical Formula 1 below, for isolating metal ions, a method for preparing the same and a method for isolating selectively the metal ions using the cycle size of the same. The present invention can provide the ionic liquid type crown ether and isolate metal ions including radioactive isotopes efficiently using the same. Furthermore, the prevent invention provides crown ether valuably used as a recyclable and environment-friendly isolating medium by preparing crown ether of ionic liquid type. wherein m, n, X? and R are identical with those in the description.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: December 14, 2010
    Assignee: Korea Atomic Energy Research Institute
    Inventors: Sang Hyun Park, Seung Ho Jang, Hui Jeong Gwon, Myung Woo Byun